Псевдоним: Нолвадекс; TAM
№ CAS: 54965-24-1
Чистота: 99%
MF: C26H29NO
МВт: 371.51
Einecs Нет: 234-118-0
MOQ(Минимум для заказа): 10грамм
Стандарт: Стандарт предприятия
Появление: белый порошок.
использование: The goods to anti-estrogen fertility inducer, the objects in dysfunctional uterine bleeding, polycystic ovary, menstrual disorders and drug-induced amenorrhea and other gynecologic diseases; It is used as a first line defense against breast cancer. Nolvadex or Tamoxifen citrate, a non-steroidal antiestrogen for oral administration, is commonly by athletes as a post cycle therapy drug to reduce or prevent the formation of excess estrogens that can lead to oily skin, прыщи, задержка жидкости, and gynecomastia.
Описание:
Nolvadex is a popular and powerfully effective Selective Estrogen Receptor Modulator (СЭРМ) that is often referred to as an anti-estrogen. тем не мение, while being an antagonist it is also an agonist as it will actually act as estrogen in certain parts of the body while acting as an anti-estrogen in other areas. As one of the oldest SERM’s on the market that is still regularly used medicinally, while Nolvadex is also used by anabolic steroid users it is not an anabolicsteroid. This is an important note as some are often confused by its use in steroid cycles. Nolvadex is simply a SERM.
Медицинское использование
Breast cancer
Tamoxifen is currently used for the treatment of both early and advanced ER+ (estrogen receptor positive) breast cancer in pre- and post-menopausal women. Провирон — пероральный анаболический стероид., it is the most common hormone treatment for male breast cancer. It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) рак. The use of tamoxifen is recommended for 10 годы.
В 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen, although the difference is not statistically significant.
Менеджер по продажам